Glucose-lowering agents and cancer mortality rates in type 2 diabetes: Assessing effects of time-varying exposure

Diabetologia

Volumn 53, Issue 8, 2010, Pages 1631-1637

  Bowker, S L ^a   Yasui, Y ^a   Veugelers, P ^a   Johnson, J A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cancer mortality; Glucose lowering agents; Insulin therapy; Time varying exposure; Type 2 diabetes

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANADA; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT RESPONSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; FACTUAL DATABASE; MORTALITY; NEOPLASM; TIME; TREATMENT OUTCOME;

DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; NEOPLASMS; SASKATCHEWAN; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953537179     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1750-8     Document Type: Article

References (40)

1. E Friberg N Orsini CS Mantzoros A Wolk 2007 Diabetes mellitus and risk of endometrial cancer: a meta-analysis Diabetologia 50 1365 1374 10.1007/s00125-007-0681-5 1:STN:280:DC%2BD2szjslCjsQ%3D%3D 17476474 (Pubitemid 46879010)
2. SS Coughlin EE Calle LR Teras J Petrelli J Michael 2004 Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults Am J Epidemiol 159 1160 1167 10.1093/aje/kwh161 15191933 (Pubitemid 38747263)
3. SC Larsson CS Mantzoros A Wolk 2007 Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 121 856 862 10.1002/ijc.22717 1:CAS:528:DC%2BD2sXotlequ7w%3D 17397032 (Pubitemid 47106217)
4. R Huxley A Ansary-Moghaddam A Berrington de Gonzalez F Barz M Woodward 2005 Type 2 diabetes and pancreatic cancer: a meta-analysis of 36 studies Br J Cancer 92 2076 2083 10.1038/sj.bjc.6602619 1:STN:280:DC%2BD2M3ot1Kjug%3D%3D 15886696 (Pubitemid 40897433)
5. SC Larsson N Orsini K Brismar A Wolk 2006 Diabetes mellitus and risk of bladder cancer: a meta-analysis Diabetologia 49 2819 2823 10.1007/s00125-006- 0468-0 1:STN:280:DC%2BD28nmtV2qsg%3D%3D 17021919 (Pubitemid 44730282)
6. SC Larsson N Orsini A Wolk 2005 Diabetes mellitus and risk of colorectal cancer: a meta-analysis J Natl Cancer Inst 97 1679 1687 10.1093/jnci/dji375 16288121 (Pubitemid 41672234)
7. AG Renehan M Zwahlen C Minder ST O'Dwyer SM Shalet M Egger 2004 Insulin-like growth factor (IGF)-1, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis Lancet 363 1346 1353 10.1016/S0140-6736(04)16044-3 1:CAS:528:DC%2BD2cXjtl2lsL0%3D 15110491 (Pubitemid 38529873)
8. M Pollak 2008 Insulin and insulin-like growth factor signalling in neoplasia Nat Rev Cancer 8 915 928 10.1038/nrc2536 1:CAS:528:DC%2BD1cXhsVWhu7rL 19029956
9. MB Schneider H Matsuzaki J Haorah, et al. 2001 Prevention of pancreatic cancer induction in hamsters by metformin Gastroenterol 120 1263 1270 10.1053/gast.2001.23258 1:CAS:528:DC%2BD3MXjtVeqsbY%3D
10. M Zakikhani R Dowling IG Fantus N Sonenberg M Pollak 2006 Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Res 66 10269 10273 10.1158/0008-5472.CAN-06-1500 1:CAS:528:DC%2BD28XhtFGjsrvK 17062558 (Pubitemid 44799743)
11. VN Anisimov PA Egormin LM Berstein 2005 Metformin slows down aging and development of mammary tumours in transgenic HER-2/neu mice Bull Exp Biol Med 139 961 965 10.1007/s10517-005-0389-9 (Pubitemid 41372239)
12. M Buzzai RG Jones RK Amaravadi, et al. 2007 Systematic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumour cell growth Cancer Res 67 6745 6752 10.1158/0008-5472.CAN-06-4447 1:CAS:528:DC%2BD2sXnslOju7s%3D 17638885 (Pubitemid 47105521)
13. AK Wong J Howie JR Petrie CC Lang 2009 AMP-activated protein kinase pathway: a potential therapeutic target in cardio metabolic disease Clin Sci (Lond) 116 607 620 10.1042/CS20080066 1:CAS:528:DC%2BD1MXjtFeksLY%3D
14. LM Berstein 2005 Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer Cancer Lett 224 203 212 10.1016/j.canlet.2004.11.011 1:CAS:528:DC%2BD2MXks1Ggtrw%3D 15914271 (Pubitemid 40731528)
15. AJ Krentz CJ Bailey 2005 Oral antidiabetic agents: current role in type 2 diabetes mellitus Drugs 65 385 411 10.2165/00003495-200565030-00005 1:CAS:528:DC%2BD2MXit1Grsbg%3D 15669880 (Pubitemid 40227460)
16. MW Stolar BJ Hoogwerf SM Gorshow PJ Boyle DO Wales 2008 Managing type 2 diabetes: going beyond glycaemic control J Manag Care Pharm 14 5 Suppl B S2 S19 18597582
17. P Kurtzahls L Schaffer A Sorensen, et al. 2000 Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 49 999 1005 10.2337/diabetes.49.6.999
18. CJ Currie CD Poole EAM Gale 2009 The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 1766 1777 10.1007/s00125-009-1440-6 1:CAS:528:DC%2BD1MXpsFyrsLo%3D 19572116
19. HM Colhoun SDRN Epidemiology Group 2009 Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group Diabetologia 52 1755 1765 10.1007/s00125-009-1453-1 1:STN:280:DC%2BD1Mrktl2kuw%3D%3D 19603149 Erratum Diabetologia 52:2469
20. JM Jonasson R Ljung M Talback B Haglund S Gudbjornsdottir G Steineck 2009 Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden Diabetologia 52 1745 1754 10.1007/s00125-009-1444-2 1:STN:280:DC%2BD1MrktlygtQ%3D%3D 19588120
21. PD Home P Lagarenne 2009 Combined randomized controlled trial experience of malignancies in studies using insulin glargine Diabetologia 52 2499 2506 10.1007/s00125-009-1530-5 1:CAS:528:DC%2BD1MXhsVWls7vK 19756478
22. A Dejgaard H Lynggaard J Rastam M Krogsgaard Thomsen 2009 No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis Diabetologia 52 2507 2512 10.1007/s00125-009-1568-4 1:STN:280:DC%2BC3c%2Fjslemtw%3D%3D 19838665
23. SL Bowker SR Majumdar P Veugelers JA Johnson 2006 Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 254 258 10.2337/diacare.29.02.06.dc05-1558 16443869
24. Z Zhou E Rahme M Abrahamowicz L Pilote 2005 Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods Am J Epidemiol 162 1016 1023 10.1093/aje/kwi307 16192344 (Pubitemid 41619473)
25. S Suissa 2003 Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies Am J Respir Crit Care Med 168 49 53 10.1164/rccm.200210-1231OC 12663327 (Pubitemid 37046632)
26. C Van Walraven D Davis AJ Forster GA Wells 2004 Time-dependent bias was common in survival analyses published in leading clinical journals J Clin Epidemiol 57 672 682 10.1016/j.jclinepi.2003.12.008 15358395 (Pubitemid 39195217)
27. M Von Korff EH Wagner K Saunders 1992 A chronic disease score from automated pharmacy data J Clin Epidemiol 45 197 203 10.1016/0895-4356(92)90016-G
28. JMM Evans LA Donnelly AM Emslie-Smith DR Alessi AD Morris 2005 Metformin and reduced risk of cancer in diabetic patients BMJ 330 1304 1305 10.1136/bmj.38415.708634.F7 15849206 (Pubitemid 40813563)
29. G Libby LA Donnelly PT Donnan DR Alessi AD Morris JMM Evans 2009 New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 1620 1625 10.2337/dc08-2175 1:CAS:528:DC%2BD1MXht1agtrzE 19564453
30. D Li SC Yeung MM Hassan M Konopleva JL Abbruzzese 2009 Antidiabetic therapies affect risk of pancreatic cancer Gastroenterology 137 482 488 10.1053/j.gastro.2009.04.013 19375425
31. YX Yang S Hennessy JD Lewis 2004 Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients Gastroenterology 127 1044 1050 10.1053/j.gastro.2004.07.011 1:CAS:528:DC%2BD2cXpsVOitrg%3D 15480982 (Pubitemid 39345873)
32. YW Chung DS Han KH Park CS Eun KS Yoo CK Park 2008 Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: a case-control study in Korea Dis Colon Rectum 51 593 597 10.1007/s10350-007-9184- 1 18219529
33. UK Prospective Diabetes Study (UKPDS) Group 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 854 865 10.1016/S0140-6736(98)07037-8 (Pubitemid 28416719)
34. BE Barker H Fanger P Farnes 1964 Human mammary slices in organ culture. I. Methods of culture and preliminary observations on the effects of insulin Exp Cell Res 35 437 448 10.1016/0014-4827(64)90134-X 1:STN:280: DyaF2M%2FhtlWhuw%3D%3D 14208738
35. BB van der Burg GR Rutteman MA Blankenstein SW de Laat EJ van Zoelen 1988 Mitogenic stimulation of human breast cancer cells in a growth-defined medium: synergistic action of insulin and estrogen J Cell Physiol 134 101 108 10.1002/jcp.1041340112 3275677
36. PJ Goodwin 2008 Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic intervention? J Clin Oncology 26 833 834 10.1200/JCO.2007.14.7132 (Pubitemid 351398072)
37. JM Gamble SH Simpson DT Eurich SR Majumdar JA Johnson 2010 Insulin use and increased risk of mortality in type 2 diabetes: a cohort study Diabetes Obes Metab 12 47 53 10.1111/j.1463-1326.2009.01125.x 1:CAS:528:DC%2BC3cXhvFajtLY%3D 19788429
38. DT Eurich JM Gamble SH Simpson JA Johnson 2008 The darkening cloud of diabetes: do trends in cardiovascular risk management provide a silver lining? Diabetes Care 31 2136 2142 10.2337/dc08-1248 18840767
39. LC Brown SR Majumdar JA Johnson 2008 Type of antidepressant therapy and risk of type 2 diabetes in people with depression Diabetes Res Clin Pract 79 61 67 10.1016/j.diabres.2007.07.009 1:CAS:528:DC%2BD1cXisFOjug%3D%3D 17714823
40. SJ Pocock L Smeeth 2009 Insulin glargine and malignancy: an unwarranted alarm Lancet 374 511 513 10.1016/S0140-6736(09)61307-6 19616841